These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 31584140)
41. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. Ragueneau-Majlessi I; Levy RH; Brodie M; Smith D; Shah J; Grundy JS Clin Pharmacokinet; 2005; 44(5):517-23. PubMed ID: 15871637 [TBL] [Abstract][Full Text] [Related]
42. Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study. Citrome L; O'Malley SS; McDonnell D; Jiang Y; Simmons AC; Berry MP; Dipetrillo LE Innov Clin Neurosci; 2019 May; 16(5-6):15-21. PubMed ID: 31440397 [No Abstract] [Full Text] [Related]
43. Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs. Spertus J; Horvitz-Lennon M; Normand ST Med Decis Making; 2019 Jul; 39(5):583-592. PubMed ID: 31375050 [TBL] [Abstract][Full Text] [Related]
44. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia. Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052 [TBL] [Abstract][Full Text] [Related]
45. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Bowden CL; Mosolov S; Hranov L; Chen E; Habil H; Kongsakon R; Manfredi R; Lin HN Int Clin Psychopharmacol; 2010 Mar; 25(2):60-7. PubMed ID: 20101186 [TBL] [Abstract][Full Text] [Related]
46. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Tohen M; Chengappa KN; Suppes T; Zarate CA; Calabrese JR; Bowden CL; Sachs GS; Kupfer DJ; Baker RW; Risser RC; Keeter EL; Feldman PD; Tollefson GD; Breier A Arch Gen Psychiatry; 2002 Jan; 59(1):62-9. PubMed ID: 11779284 [TBL] [Abstract][Full Text] [Related]
47. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy. Ben-Menachem E; Gunning B; Arenas Cabrera CM; VanLandingham K; Crockett J; Critchley D; Wray L; Tayo B; Morrison G; Toledo M CNS Drugs; 2020 Jun; 34(6):661-672. PubMed ID: 32350749 [TBL] [Abstract][Full Text] [Related]
48. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Bridle C; Palmer S; Bagnall AM; Darba J; Duffy S; Sculpher M; Riemsma R Health Technol Assess; 2004 May; 8(19):iii-iv, 1-187. PubMed ID: 15147609 [TBL] [Abstract][Full Text] [Related]
49. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain. Corrao MM; Nelson LA CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903 [TBL] [Abstract][Full Text] [Related]
50. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine. Srisurapanont M; Suttajit S; Likhitsathian S; Maneeton B; Maneeton N Sci Rep; 2021 Apr; 11(1):7583. PubMed ID: 33828206 [TBL] [Abstract][Full Text] [Related]
51. Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. Kumar V; Lu H; Hard M; von Moltke L Drugs R D; 2019 Sep; 19(3):277-287. PubMed ID: 31463821 [TBL] [Abstract][Full Text] [Related]
52. The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. Hirschfeld RM; Baker JD; Wozniak P; Tracy K; Sommerville KW J Clin Psychiatry; 2003 Jul; 64(7):841-6. PubMed ID: 12934987 [TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Sidhu J; Job S; Bullman J; Francis E; Abbott R; Ascher J; Theis JG Br J Clin Pharmacol; 2006 Apr; 61(4):420-6. PubMed ID: 16542203 [TBL] [Abstract][Full Text] [Related]
54. Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial. Pathak S; Vince B; Kelsh D; Shram MJ; Setnik B; Lu H; Nangia N; Stanford AD; Ehrich E J Clin Pharmacol; 2019 Feb; 59(2):206-217. PubMed ID: 30102427 [TBL] [Abstract][Full Text] [Related]
55. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Winter HR; DeVane CL; Figueroa C; Ennis DJ; Hamer-Maansson JE; Davis PC; Smith MA Hum Psychopharmacol; 2007 Oct; 22(7):469-76. PubMed ID: 17729385 [TBL] [Abstract][Full Text] [Related]
56. Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate. Gustavson LE; Sommerville KW; Boellner SW; Witt GF; Guenther HJ; Granneman GR Am J Ther; 1998 Mar; 5(2):73-9. PubMed ID: 10099041 [TBL] [Abstract][Full Text] [Related]
57. Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma. Salem H; Samir E; Mazen DZ; Madian H; Elkhateeb AE; Elaraby M; Rasekh MI; Gamal A Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jun; 274():121105. PubMed ID: 35272122 [TBL] [Abstract][Full Text] [Related]
58. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. Niufan G; Tohen M; Qiuqing A; Fude Y; Pope E; McElroy H; Ming L; Gaohua W; Xinbao Z; Huichun L; Liang S J Affect Disord; 2008 Jan; 105(1-3):101-8. PubMed ID: 17531327 [TBL] [Abstract][Full Text] [Related]
59. Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. Polasek TM; Tucker GT; Sorich MJ; Wiese MD; Mohan T; Rostami-Hodjegan A; Korprasertthaworn P; Perera V; Rowland A Br J Clin Pharmacol; 2018 Mar; 84(3):462-476. PubMed ID: 29194718 [TBL] [Abstract][Full Text] [Related]
60. Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia. Monahan C; McCoy L; Powell J; Gums JG Ann Pharmacother; 2022 Sep; 56(9):1049-1057. PubMed ID: 35040357 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]